Cencora (NYSE:COR) Issues Earnings Results

Cencora (NYSE:COR) posted its quarterly earnings data on Wednesday. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.80 by ($0.05), FiscalAI reports. The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora’s revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the business earned $4.42 EPS. Cencora updated its FY 2026 guidance to 17.650-17.900 EPS.

Here are the key takeaways from Cencora’s conference call:

• Cencora reported adjusted diluted EPS of $4.75 (up 7.5%) in Q2, raised full?year adjusted EPS guidance to $17.65–$17.90, generated $1.1B of free cash flow in the quarter, and resumed opportunistic share repurchases targeting $1B by calendar?year end.
• Management emphasized investments in digital transformation and specialty capabilities — launching AI?supported customer tools, driving a second consecutive quarter of operating income growth in global specialty logistics, and accelerating MSO integration (OneOncology/RCA) to support long?term specialty growth.
• Consolidated revenue guidance was cut to 4%–6% (from 7%–9%) due to a ~$2B headwind from WAC/IRA price reductions, faster?than?expected brand conversions at a large mail?order customer, slower GLP?1 growth, and recent customer losses.
• Operating expenses rose 22.5% (driven by the OneOncology acquisition) and net interest expense increased to ~$140M this quarter from acquisition financing, though management expects interest to remain steady in Q3 and modestly decline in Q4 while raising consolidated operating income growth guidance to 12%–14%.

Cencora Trading Down 17.6%

COR traded down $53.89 during midday trading on Wednesday, hitting $252.01. 5,433,671 shares of the company were exchanged, compared to its average volume of 1,387,742. The firm has a market capitalization of $49.02 billion, a P/E ratio of 30.28, a P/E/G ratio of 1.42 and a beta of 0.64. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54. The firm’s 50 day moving average price is $332.27 and its 200-day moving average price is $343.21. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Analyst Ratings Changes

A number of equities research analysts have weighed in on COR shares. Robert W. Baird set a $415.00 target price on Cencora in a report on Tuesday, January 13th. Wells Fargo & Company raised their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. raised their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Finally, William Blair started coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $398.17.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised its fiscal 2026 adjusted EPS outlook to $17.65–$17.90 (above prior guide and roughly in line or slightly above consensus), signaling confidence in margin/cash generation. Cencora raises annual profit forecast despite quarterly miss
• Positive Sentiment: Company announced a $1 billion share-repurchase plan to be completed by end of calendar 2026, which supports EPS and signals capital-return priority. Cencora slides 17.6% after fiscal Q2 results miss revenue expectations and highlight near-term headwinds
• Neutral Sentiment: Revenue grew modestly (about +3.8% y/y to ~$78.4B) and adjusted EPS improved year-over-year, showing continued specialty-driven growth despite unit-level pressures. Cencora Reports Fiscal 2026 Second Quarter Results
• Negative Sentiment: Quarterly top-line missed Wall Street expectations ($78.36B vs. ~$81.09B consensus) and adjusted EPS slightly missed consensus ($4.75 vs. $4.80), triggering concern about demand and revenue quality. Cencora (COR) Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: Management trimmed revenue guidance ($334.2B–$340.6B) below analyst expectations, pointing to slower U.S. Healthcare Solutions sales as branded-drug price cuts, lower volume from a large mail-order client and prior customer losses weighed on results. Cencora Shares Drop on Revenue Outlook Cut
• Negative Sentiment: Market reaction pushed the stock to a 52-week low amid heavy volume; investors are focused on near-term customer/ pricing risks despite the raised EPS guide and buyback. Cencora hits 52-week low after guidance cut

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Beacon Pointe Advisors LLC lifted its holdings in Cencora by 1.1% during the 4th quarter. Beacon Pointe Advisors LLC now owns 3,492 shares of the company’s stock worth $1,180,000 after buying an additional 37 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Cencora by 2.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,784 shares of the company’s stock worth $603,000 after buying an additional 38 shares during the period. Sumitomo Life Insurance Co. lifted its holdings in Cencora by 0.9% during the 4th quarter. Sumitomo Life Insurance Co. now owns 4,462 shares of the company’s stock worth $1,507,000 after buying an additional 39 shares during the period. Evergreen Capital Management LLC lifted its holdings in Cencora by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock worth $370,000 after buying an additional 45 shares during the period. Finally, Mission Creek Capital Partners Inc. lifted its holdings in Cencora by 5.1% during the 4th quarter. Mission Creek Capital Partners Inc. now owns 1,158 shares of the company’s stock worth $391,000 after buying an additional 56 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.